Company
Scandion Oncology A/S
Headquarters: Copenhagen, Denmark
Employees: 15
CEO: Dr. Bo Rode Hansen
Market Cap
kr74.6 Million
SEK as of July 1, 2023
US$6.9 Million
Scandion Oncology A/S Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
|
Novo Nordisk
|
$329.83 B |
Vertex Pharmaceuticals Incorporated
|
$88.79 B |
CSL Limited
|
$85.00 B |
| Marinomed Biotech AG | $84.73 B |
|
Regeneron Pharmaceuticals, Inc.
|
$78.88 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Stocks & Indices
Scandion Oncology A/S has the following listings and related stock indices.
Stock: OMX: SCOL wb_incandescent